Engineered protease-resistant antibodies with selectable cell-killing functions.

  title={Engineered protease-resistant antibodies with selectable cell-killing functions.},
  author={Michelle Kinder and Allison R Greenplate and Katharine D. Grugan and Keri L Soring and Katharine A Heeringa and Stephen G McCarthy and Gregory Bannish and Meredith Perpetua and Frank J. Lynch and Robert E. Jordan and William R. Strohl and Randall J Brezski},
  journal={The Journal of biological chemistry},
  volume={288 43},
Molecularly engineered antibodies with fit-for-purpose properties will differentiate next generation antibody therapeutics from traditional IgG1 scaffolds. One requirement for engineering the most appropriate properties for a particular therapeutic area is an understanding of the intricacies of the target microenvironment in which the antibody is expected to function. Our group and others have demonstrated that proteases secreted by invasive tumors and pathological microorganisms are capable of… CONTINUE READING